{
  "meta": {
    "title": "50_Anti-Diabetic_Drugs_-_Injectable",
    "url": "https://brainandscalpel.vercel.app/50-anti-diabetic-drugs-injectable-2e59e601.html",
    "scrapedAt": "2025-11-30T12:34:33.478Z"
  },
  "questions": [
    {
      "text": "What is the half-life of endogenously secreted insulin?",
      "choices": [
        {
          "id": 1,
          "text": "1-2 minutes"
        },
        {
          "id": 2,
          "text": "5-6 minutes"
        },
        {
          "id": 3,
          "text": "20-30 minutes"
        },
        {
          "id": 4,
          "text": "1-2 hours"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Endogenously </strong>secreted insulin has a <strong>half-life </strong>of only<strong> 5-6 minutes</strong> due to its extensive hepatic clearance.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3616",
      "difficulty": "medium"
    },
    {
      "text": "A 28-year-old nurse was brought to the casualty with seizures and altered mental status. Her plasma glucose was 35 mg/dl.  Which test would help to rule out the possibility of exogenous insulin administration?",
      "choices": [
        {
          "id": 1,
          "text": "Glucagon"
        },
        {
          "id": 2,
          "text": "C-peptide"
        },
        {
          "id": 3,
          "text": "Pancreatic polypeptide"
        },
        {
          "id": 4,
          "text": "Preproinsulin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>C-peptide</strong>&nbsp;can be used to rule out the possibility of factitious hypoglycemia resulting from&nbsp;<strong>exogenously</strong> <strong>administered insulin</strong>.</p>\n<p>Endogenous insulin is initially synthesized as preproinsulin that is processed to proinsulin inside beta cells. <strong>Proinsulin</strong> is released by secretory granules after processing it to form <strong>insulin and C-peptide</strong>.&nbsp;</p>\n<p><strong>Synthetic insulin</strong> usually <strong>lacks C-peptide</strong>, so in factitious hypoglycemia secondary to exogenous insulin administration, plasma insulin will be elevated, but there will be suppression of C-peptide and proinsulin, and insulin to C-peptide ratio will be greater than one.</p>\n<p>On the other hand, <strong>insulinomas</strong> and <strong>insulin secretagogues</strong> like sulfonylureas <strong>stimulate endogenous insulin</strong> production. As a result, plasma insulin, C-peptide, and proinsulin levels will be all elevated. The only way to differentiate between insulinoma and insulin secretagogues-induced hypoglycemia is by detecting the drug, e.g., sulfonylurea, in the blood or urine.</p>\n<p>C-peptide has no known physiological function or receptor. It has a half-life of about 30 min.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3617",
      "difficulty": "easy"
    },
    {
      "text": "A patient requires the shortest acting formulation of insulin to prevent postprandial hyperglycemia. Which of the following formulations would you choose?",
      "choices": [
        {
          "id": 1,
          "text": "Insulin lispro"
        },
        {
          "id": 2,
          "text": "Insulin aspart"
        },
        {
          "id": 3,
          "text": "Regular insulin"
        },
        {
          "id": 4,
          "text": "Inhaled insulin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Inhaled insulin</strong>&nbsp;is the <strong>shortest acting</strong> formulation of <strong>insulin</strong>.&nbsp;</p><hr><h3>Related Pearl: Insulin Classification According to Duration of Action</h3><p><strong>Inhaled insulin&nbsp;(2-3 hours)</strong></p>\n<ul>\n<li>Afrezza&nbsp;</li>\n</ul>\n<p><strong>Rapid acting (3-4 hours)</strong></p>\n<ul>\n<li>Aspart</li>\n<li>Glulisine</li>\n<li>Lispro</li>\n</ul>\n<p><strong>Short acting&nbsp;(6-8 hours)</strong></p>\n<ul>\n<li>Regular</li>\n</ul>\n<p><strong>Intermediate acting (10-16 hours)</strong></p>\n<ul>\n<li>NPH</li>\n<li>Lente</li>\n</ul>\n<p><strong>Long acting&nbsp;(12-24 hours)</strong></p>\n<ul>\n<li>Detemir</li>\n<li>Glargine</li>\n<li>Degludec <strong>(24-42 hours)</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3621",
      "difficulty": "medium"
    },
    {
      "text": "A patient on basal-bolus regimen for type 1 diabetes wants an alternative to multiple daily injections. She read about the new drug Afrezza and wants to know more about it. Which of the following is not true about this formulation?",
      "choices": [
        {
          "id": 1,
          "text": "Inhaled insulin"
        },
        {
          "id": 2,
          "text": "Can be used as single or multiple pre meal doses"
        },
        {
          "id": 3,
          "text": "If multiple doses used then no need of basal insulin"
        },
        {
          "id": 4,
          "text": "Avoided in active smokers"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Afrezza</strong> should be <strong>used in combination</strong> with basal <strong>long-acting insulin</strong> to supplement it.</p>\n<p>Option A - Afrezza is an <strong>inhaled insulin</strong> that is available in dry powder form. It is the <strong>shortest acting insulin</strong> (2-3 hours) and it reduces the use of short-acting injectable insulin. Adverse events include cough and throat irritation.</p>\n<p>Option B - It is taken pre-meal to reduce postprandial hyperglycemia.&nbsp;</p>\n<p>Option D - Afrezza is <strong>contraindicated</strong> in active <strong>smokers</strong>, asthmatics and COPD patients.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6936",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following preparations of insulin is not rapid-acting?",
      "choices": [
        {
          "id": 1,
          "text": "Glargine"
        },
        {
          "id": 2,
          "text": "Lispro"
        },
        {
          "id": 3,
          "text": "Glulisine"
        },
        {
          "id": 4,
          "text": "Aspart"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>All of the following preparations of insulin are rapid-acting except <strong>glargine.</strong></p>\n<p>Insulin preparations and duration of action</p>\n<p><strong>Short-acting:</strong></p>\n<ul>\n<li>Insulin lispro, Insulin aspart, Insulin glulisine: 3-4 hours&nbsp;</li>\n<li>Regular insulin: 4-6 hours</li>\n</ul>\n<p><strong>Long-acting:&nbsp;&nbsp;</strong></p>\n<ul>\n<li>Insulin NPH: 10-16 hours&nbsp;</li>\n<li>Insulin detemir: 12-24 hours&nbsp;</li>\n<li><strong>Insulin glargine: 12-24 hours</strong>&nbsp;</li>\n<li>Insulin degludec: 24-42 hours&nbsp;&nbsp;</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1861",
      "difficulty": "easy"
    },
    {
      "text": "Identify the correct insulin combination option.",
      "choices": [
        {
          "id": 1,
          "text": "1 - Glargine, 2 - Detemir"
        },
        {
          "id": 2,
          "text": "1 - Glargine, 2 - Degludec"
        },
        {
          "id": 3,
          "text": "1 - Detemir, 2 - Aspart"
        },
        {
          "id": 4,
          "text": "1 - Glulisine, 2 - Glargine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Detemir</strong> is a <strong>long-acting</strong> insulin and <strong>aspart</strong> is a <strong>rapid-acting</strong> insulin and matches with 1 and 2 respectively in the image showing <strong>basal-bolus regimen</strong>.&nbsp;</p><hr><h3>Related Pearl: Insulin Classification According to Duration of Action</h3><p><strong>Inhaled insulin&nbsp;(2-3 hours)</strong></p>\n<ul>\n<li>Afrezza&nbsp;</li>\n</ul>\n<p><strong>Rapid acting (3-4 hours)</strong></p>\n<ul>\n<li>Aspart</li>\n<li>Glulisine</li>\n<li>Lispro</li>\n</ul>\n<p><strong>Short acting&nbsp;(6-8 hours)</strong></p>\n<ul>\n<li>Regular</li>\n</ul>\n<p><strong>Intermediate acting (10-16 hours)</strong></p>\n<ul>\n<li>NPH</li>\n<li>Lente</li>\n</ul>\n<p><strong>Long acting&nbsp;(12-24 hours)</strong></p>\n<ul>\n<li>Detemir</li>\n<li>Glargine</li>\n<li>Degludec <strong>(24-42 hours)</strong></li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/947efd6318f64d5aa2658e117e9d83b7.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3631",
      "difficulty": "medium"
    },
    {
      "text": "A 30-year-old patient with type 1 diabetes presented with complaints of vomiting and abdominal pain. On examination, she had fast, deep breathing with a fruity odor. Her capillary blood glucose was 450mg/dL. What is the clinical concern associated with administering insulin alone?",
      "choices": [
        {
          "id": 1,
          "text": "Hypokalemia"
        },
        {
          "id": 2,
          "text": "Hypernatremia"
        },
        {
          "id": 3,
          "text": "Hyperkalemia"
        },
        {
          "id": 4,
          "text": "Hyponatremia"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Deep breathing (<strong>Kussmaul</strong> respiration) and fruity breath (acetone odor) in a symptomatic patient with <strong>type 1 diabetes</strong> are suggestive of <strong>diabetic ketoacidosis</strong>. <strong>Insulin therapy alone</strong> in a patient with diabetic ketoacidosis (DKA) may result in <strong>hypokalemia</strong>.</p>\n<p>DKA is usually associated with a major K<sup>+</sup> deficit. Potassium loss is caused by an <strong>extracellular shift</strong> of potassium (in exchange with hydrogen ions) due to&nbsp;<strong>acidosis</strong>. Much of the shifted extracellular potassium is <strong>lost </strong>due to <strong>emesis </strong>and <strong>osmotic diuresis</strong>.</p>\n<p>When insulin therapy is initiated for DKA, the serum <strong>K<sup>+</sup> is shifted intracellularly</strong>. Dangerous hypokalemia might occur if <strong>K<sup>+</sup> supplementation</strong> is not initiated subsequently. Insulin should be withheld if the serum level of potassium is below 3.3&thinsp;mmol/L.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1857",
      "difficulty": "easy"
    },
    {
      "text": "You see a nurse administering an insulin preparation that appears cloudy white. Which formulation of insulin could it be?",
      "choices": [
        {
          "id": 1,
          "text": "Insulin glargine"
        },
        {
          "id": 2,
          "text": "Insulin glulisine"
        },
        {
          "id": 3,
          "text": "Insulin detemir"
        },
        {
          "id": 4,
          "text": "Insulin NPH"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The formulation is most likely <strong>NPH insulin</strong> as it produces a <strong>cloudy or whitish solution</strong> in contrast to the clear appearance of other insulin solutions.</p>\n<p>NPH or isophane insulin is a suspension of native insulin complexed with zinc and protamine in phosphate buffer.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3624",
      "difficulty": "medium"
    },
    {
      "text": "A patient was recently diagnosed with diabetes. She was prescribed the longest-acting  insulin as it has the least risk of hypoglycemia. Which insulin preparation is she on?",
      "choices": [
        {
          "id": 1,
          "text": "Insulin NPH"
        },
        {
          "id": 2,
          "text": "Insulin glargine"
        },
        {
          "id": 3,
          "text": "Insulin detemir"
        },
        {
          "id": 4,
          "text": "Insulin degludec"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Insulin degludec</strong> has the <strong>maximum duration of action</strong> (24-42 hours) among long-acting insulins. It is sometimes considered an ultra long-acting insulin.</p><hr><h3>Related Pearl: Insulin Classification According to Duration of Action</h3><p><strong>Inhaled insulin&nbsp;(2-3 hours)</strong></p>\n<ul>\n<li>Afrezza&nbsp;</li>\n</ul>\n<p><strong>Rapid acting (3-4 hours)</strong></p>\n<ul>\n<li>Aspart</li>\n<li>Glulisine</li>\n<li>Lispro</li>\n</ul>\n<p><strong>Short acting&nbsp;(6-8 hours)</strong></p>\n<ul>\n<li>Regular</li>\n</ul>\n<p><strong>Intermediate acting (10-16 hours)</strong></p>\n<ul>\n<li>NPH</li>\n<li>Lente</li>\n</ul>\n<p><strong>Long acting&nbsp;(12-24 hours)</strong></p>\n<ul>\n<li>Detemir</li>\n<li>Glargine</li>\n<li>Degludec <strong>(24-42 hours)</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3625",
      "difficulty": "easy"
    },
    {
      "text": "A diabetic patient is in the postoperative area following cardiac surgery. He is to be given intravenous insulin for optimal glycemic control and to avoid sternal wound infection. Which of the following should not be administered?",
      "choices": [
        {
          "id": 1,
          "text": "Insulin glulisine"
        },
        {
          "id": 2,
          "text": "Insulin detemir"
        },
        {
          "id": 3,
          "text": "Regular insulin"
        },
        {
          "id": 4,
          "text": "Insulin aspart"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Insulin <strong>detemir</strong> is a long-acting insulin and<strong>&nbsp;should not </strong>be given<strong> intravenously </strong>or intramuscularly<strong>. </strong>It is only given via subcutaneous route.</p>\n<p>Options A, C, and D: <strong>Regular insulin</strong> and short-acting insulins <strong>(glulisine and aspart</strong>) can be given <strong>intravenously.</strong> While short-acting insulins are approved for intravenous administration under supervision,<strong> regular insulin is preferred</strong> in perioperative glycemic control due to the <strong>lesser risk of hypoglycemia.</strong></p>\n<p>Intravenous insulin is used in diabetic ketoacidosis and other conditions where insulin requirements change drastically like perioperative period, labor, and in intensive care situations.&nbsp;&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3622",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following insulin precipitates into a cloudy white precipitate when mixed with short acting insulins?",
      "choices": [
        {
          "id": 1,
          "text": "Insulin detemir"
        },
        {
          "id": 2,
          "text": "Insulin degludec"
        },
        {
          "id": 3,
          "text": "Insulin glargine"
        },
        {
          "id": 4,
          "text": "Insulin glulisine"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Insulin glargine</strong>&nbsp;forms a cloudy white precipitate when mixed with short-acting insulins.</p>\n<p>Due to the&nbsp;<strong>acidic pH</strong>&nbsp;(4.0) of insulin glargine, it cannot be mixed with short-acting insulin preparations that are formulated at a neutral pH as it&nbsp;<strong>aggregates at neutral pH</strong>&nbsp;into a&nbsp;<strong>cloudy white precipitate.&nbsp;</strong>This<strong>&nbsp;</strong>reduces the effectiveness of the insulin dose.</p>\n<p><strong>Insulin degludec&nbsp;</strong>and<strong>&nbsp;detemir&nbsp;</strong>have a<strong>&nbsp;pH of 7.4</strong>&nbsp;that is very near to neutral pH and they do not form such aggregates when mixed with short-acting insulins.&nbsp;</p>\n<p>But the manufacturers do not advise manual mixing with short-acting insulin as it may alter the activity profile of the combination that can turn unpredictable. Degludec is available as an approved fixed-dose combination with aspart that can be used with predictable effects.</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3623",
      "difficulty": "medium"
    },
    {
      "text": "Composition of Lente insulin is:",
      "choices": [
        {
          "id": 1,
          "text": "70% amorphous 30% crystalline"
        },
        {
          "id": 2,
          "text": "70% crystalline 30% amorphous"
        },
        {
          "id": 3,
          "text": "Only 70% amorphous"
        },
        {
          "id": 4,
          "text": "Other name of NPH insulin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Lente</strong> insulin is an <strong>intermediate-acting</strong> insulin and is a <strong>combination of Ultralente and Semilente </strong>in the<strong> ratio of 7:3</strong></p>\n<p>Two types of insulin zinc suspensions have been produced. The one with large particles is crystalline and practically insoluble in water (<strong>Ultralente</strong>). It is long-acting. The other has smaller particles and is amorphous (<strong>Semilente</strong>), is short-acting. Their 7:3 ratio mixture is called &lsquo;Lente insulin&rsquo; and is intermediate-acting.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC9515",
      "difficulty": "medium"
    },
    {
      "text": "You are counseling a diabetic patient and teaching her the technique to self-administer insulin at home every day. Which of the following sites would you not suggest as the preferred site for insulin administration?",
      "choices": [
        {
          "id": 1,
          "text": "Anterior part of thigh"
        },
        {
          "id": 2,
          "text": "Lateral part of thigh"
        },
        {
          "id": 3,
          "text": "Buttocks"
        },
        {
          "id": 4,
          "text": "Medial part of thigh"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The medial part of the thigh is not a preferred site for insulin administration in patients. This is because of the relatively higher density of blood vessels and nerves in this area. Another consideration is that the inner thighs rub together while walking and may cause soreness at the injection sites.</p>\n<p>The <strong>preferred sites</strong> for insulin administration are:</p>\n<ul>\n<li>Upper arm</li>\n<li>Anterior and lateral aspects of the thigh</li>\n<li>Buttocks</li>\n<li>Abdomen (with the exception of a circle with a 2-inch radius around the navel)</li>\n</ul>\n<p><strong>Rotation</strong> of the injection site is important to <strong>prevent lipodystrophy</strong>. However, rotating <strong>within one area</strong> is recommended (e.g., rotating injections systematically within the abdomen) rather than rotating to a different area with each injection. This helps decrease variability in absorption from day to day.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/336c015a430f474d9d6818f4ee6c4336x472x449.PNG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC4577",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is incorrect regarding exenatide?",
      "choices": [
        {
          "id": 1,
          "text": "It is a GLP- 1 analogue"
        },
        {
          "id": 2,
          "text": "It can be used for the treatment of type 1 diabetes mellitus"
        },
        {
          "id": 3,
          "text": "It is given subcutaneously"
        },
        {
          "id": 4,
          "text": "It decreases glucagon"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Exenatide</strong> is<strong> not indicated </strong>in<strong> type 1 diabetes mellitus. </strong></p>\n<p>Exenatide is a GLP-1 analog that acts as an <strong>insulin secretagogue</strong>. As the beta cells are already destroyed and do not secrete insulin in type 1 diabetes, there is no role of drugs that enhance insulin secretion.</p>\n<p>Option A - Exenatide is a<strong> GLP-1 analog</strong> and it is <strong>synthesized from exendin-4</strong>&nbsp;</p>\n<p>Option C - It is&nbsp;a peptide and hence has to be administered <strong>subcutaneously</strong>&nbsp;</p>\n<p>Option D - It increases insulin secretion, <strong>decreases glucagon </strong>secretion, <strong>delays gastric emptying</strong>, and reduces food intake&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1856",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a GLP-1 receptor agonist?",
      "choices": [
        {
          "id": 1,
          "text": "Liraglutide"
        },
        {
          "id": 2,
          "text": "Semaglutide"
        },
        {
          "id": 3,
          "text": "Pramlintide"
        },
        {
          "id": 4,
          "text": "Exenatide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Pramlintide </strong>is an islet amyloid polypeptide (IAPP) or<strong>&nbsp;amylin analogue.</strong></p>\n<p>Amylin analogues&nbsp;reduce glucagon secretion, slows gastric emptying, and centrally decreases appetite.&nbsp;</p>\n<p>Options A, B and D - Liraglutide, semaglutide and exenatide are GLP-1 agonists.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3628",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following statements is not true about pramlintide?",
      "choices": [
        {
          "id": 1,
          "text": "It can be used in both type 1 and type 2 diabetes mellitus"
        },
        {
          "id": 2,
          "text": "It has got weight reducing property by causing a central anorectic effect"
        },
        {
          "id": 3,
          "text": "It should not be administered with insulin in the same syringe"
        },
        {
          "id": 4,
          "text": "It is given orally"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Pramlintide</strong> is administered as a <strong>subcutaneous</strong> injection.</p>\n<p>Option A - It is a synthetic analogue of amylin and is approved for both type 1 and type 2 diabetes mellitus</p>\n<p>Option B - It has weight reducing property by causing a central anorectic effect.&nbsp;It acts by reducing glucagon secretion, delaying gastric emptying and decreasing appetite.</p>\n<p>Option C - It should not be administered with insulin in the same syringe because of a difference in pH</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1873",
      "difficulty": "medium"
    },
    {
      "text": "A 40-year-old diabetic woman comes for follow up. Her BMI is 32 kg/m2 despite several months of diet and exercise. Which of the following is the drug preferred for her condition?",
      "choices": [
        {
          "id": 1,
          "text": "Liraglutide"
        },
        {
          "id": 2,
          "text": "Linagliptin"
        },
        {
          "id": 3,
          "text": "Insulin lispro"
        },
        {
          "id": 4,
          "text": "Pioglitazone"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Liraglutide</strong> is <strong>approved</strong> for the management of <strong>obesity</strong>.&nbsp;</p>\n<p><strong>GLP-1</strong> is a physiological <strong>regulator of appetite</strong> and calorie intake, and the GLP-1 receptor is present in several areas of the brain involved in appetite regulation. Liraglutide is a GLP-1 analog and lowers body weight by decreasing calorie intake.</p><p>Note:&nbsp;FDA has recently approved<strong> semaglutide</strong> subcutaneous injection once weekly for chronic weight management. This is for use in patients with obesity and overweight individuals with at least one weight-related condition such as type 2 diabetes, hypertension or dyslipidemia.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3630",
      "difficulty": "medium"
    },
    {
      "text": "A 45-year-old man comes for a routine health check-up. He has a family history of medullary thyroid cancer. His thyroid examination is normal but his HbA1c is found to be 7.5%. In view of his history, which of the following should not be prescribed for him?",
      "choices": [
        {
          "id": 1,
          "text": "SGLT 2 inhibitors"
        },
        {
          "id": 2,
          "text": "DPP4 inhibitors"
        },
        {
          "id": 3,
          "text": "GLP 1 agonists"
        },
        {
          "id": 4,
          "text": "Sulfonylureas"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>GLP-1 analogues</strong> are <strong>contraindicated</strong> in patients with a personal or <strong>family history of medullary thyroid cancer</strong> and in patients with <strong>MEN 2</strong> syndrome.</p>\n<p>GLP-1 analogues cause thyroid C-cell tumours at clinically relevant exposures in rodents. However, studies have not yet shown if they cause thyroid C-cell tumours like medullary thyroid carcinoma in humans.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA1888",
      "difficulty": "medium"
    },
    {
      "text": "A 50-year-old man with superior mesenteric artery occlusion underwent extensive bowel resection. Following surgery, he developed short bowel syndrome and has been on parenteral nutrition. Which of the following drugs would be beneficial for his condition?",
      "choices": [
        {
          "id": 1,
          "text": "Liraglutide"
        },
        {
          "id": 2,
          "text": "Lixisenatide"
        },
        {
          "id": 3,
          "text": "Teduglutide"
        },
        {
          "id": 4,
          "text": "Semaglutide"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Teduglutide</strong> is a <strong>GLP-2 analog</strong> and is <strong>approved</strong> for the treatment of <strong>short bowel syndrome</strong>.</p>\n<p>GLP-2&nbsp;binds to enteric neurons and endocrine cells, stimulating the release of a number of hormones such as insulin-like growth factor. This <strong>stimulates mucosal epithelial growth</strong> and enhances fluid absorption.</p>\n<p><strong>GLP-1 analogs:</strong></p>\n<ul>\n<li>Exenatide&nbsp;</li>\n<li><strong>Liraglutide</strong>&nbsp;</li>\n<li>Albiglutide&nbsp;</li>\n<li>Dulaglutide</li>\n<li><strong>Lixisenatide</strong>&nbsp;</li>\n<li><strong>Semaglutide</strong></li>\n</ul>\n<p>Note: GLP-1 analogs are used for the treatment of <strong>Type II diabetes mellitus.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC3627",
      "difficulty": "medium"
    },
    {
      "text": "Identify the true statement regarding teduglutide.",
      "choices": [
        {
          "id": 1,
          "text": "It is not recommended for patients with colorectal cancer"
        },
        {
          "id": 2,
          "text": "Itâ€™s half life is 6 - 8 hours"
        },
        {
          "id": 3,
          "text": "It can be administered orally"
        },
        {
          "id": 4,
          "text": "It promotes gastric acid secretion and gastric emptying"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Teduglutide&nbsp;</strong>can potentially <strong>cause&nbsp;bowel cancer,&nbsp;</strong>therefore it is not recommended for patients with active malignancies.</p>\n<p>It is a GLP-2 analog that has been recently approved for the <strong>treatment of short bowel syndrome.&nbsp;</strong>It <strong>inhibits gastric acid</strong> secretion and gastric emptying, <strong>stimulates mucosal epithelial growth</strong> and<strong>&nbsp;</strong>intestinal blood flow, and enhances nutrient and fluid absorption</p>\n<p>The drug has a<strong>&nbsp;t1/2 of 1&ndash;2 hours&nbsp;</strong>and is&nbsp;<strong>administered subcutaneously</strong>&nbsp;once daily.</p>\n<p>Note: GLP-1 analogs are used for the treatment of Type II diabetes mellitus.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF0645",
      "difficulty": "hard"
    }
  ]
}